darunavir has been researched along with uic-94003 in 9 studies
| Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) | Studies (uic-94003) | Trials (uic-94003) | Recent Studies (post-2010) (uic-94003) |
|---|---|---|---|---|---|
| 1,148 | 224 | 780 | 18 | 0 | 4 |
| Protein | Taxonomy | darunavir (IC50) | uic-94003 (IC50) |
|---|---|---|---|
| Protease | Human immunodeficiency virus 1 | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buthod, J; Cho, H; Cho, W; Ghosh, AK; Holland, L; Hussain, KA; Kincaid, JF; Koo, Y; Krishnan, K; Rudall, C; Walters, DE | 1 |
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; Jonckers, TH; King, NM; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Tahri, A; Verschueren, WG; Wigerinck, PB | 1 |
| Amano, M; Baldridge, A; Das, D; Davis, DA; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Matsumi, S; Mitsuya, H; Shioda, T; Yarchoan, R | 1 |
| Dawson, ZL; Ghosh, AK; Mitsuya, H | 1 |
| Baldridge, A; Gemma, S; Ghosh, AK; Koh, Y; Kovalevsky, AY; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Ghosh, AK | 1 |
| Amano, M; Anderson, DD; Baldridge, A; Chumanevich, AA; Ghosh, AK; Hong, L; Koh, Y; Kovalevsky, AY; Kulkarni, S; Mitsuya, H; Tang, J; Tojo, Y; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Aoki, M; Bulut, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Rao, KV; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Brindisi, M; Ghosh, AK; Mitsuya, H; Sean Fyvie, W; Steffey, M; Wang, YF; Weber, IT | 1 |
2 review(s) available for darunavir and uic-94003
| Article | Year |
|---|---|
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.
Topics: Clinical Trials as Topic; Crystallography, X-Ray; Darunavir; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Structure; Structure-Activity Relationship; Sulfonamides | 2007 |
Harnessing nature's insight: design of aspartyl protease inhibitors from treatment of drug-resistant HIV to Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antiviral Agents; Aspartic Acid Endopeptidases; Biological Products; Darunavir; Drug Design; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Molecular Mimicry; Molecular Structure; Peptides; Structure-Activity Relationship; Sulfonamides | 2009 |
7 other study(ies) available for darunavir and uic-94003
| Article | Year |
|---|---|
Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.
Topics: Cell Line; Drug Design; HIV Protease Inhibitors; Humans; Ligands; Models, Chemical; Saquinavir; Sulfonamides | 1998 |
Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Crystallography, X-Ray; Darunavir; Dogs; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Molecular Conformation; Mutation; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfonamides; Thermodynamics | 2005 |
Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.
Topics: Animals; CCR5 Receptor Antagonists; CD4 Antigens; Chlorocebus aethiops; COS Cells; Darunavir; Dimerization; Dose-Response Relationship, Drug; Enzyme Activation; Fluorescence Resonance Energy Transfer; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Protein Processing, Post-Translational; Pyridines; Pyrones; Receptors, CCR5; Sulfonamides; Virus Replication | 2007 |
Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.
Topics: Antiviral Agents; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Ethers, Cyclic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hydrogen Bonding; Ligands; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Polyesters; Stereoisomerism; Structure-Activity Relationship; T-Lymphocytes; Water | 2008 |
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Topics: Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Design; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Macrocyclic Compounds; Models, Molecular; Molecular Conformation; Mutation | 2009 |
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Topics: Benzothiazoles; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Pyrans; Structure-Activity Relationship; Sulfonamides | 2017 |
Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
Topics: Binding Sites; Crystallography, X-Ray; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Ligands; Macrocyclic Compounds; Molecular Dynamics Simulation; Mutation; Protein Structure, Tertiary; Pyrrolidinones; Structure-Activity Relationship | 2017 |